EMA Application withdrawn: Dimherity (dimethyl fumarate) — Sandoz GmbH

View source ↗

Summary

The EMA withdrew the application for Dimherity (dimethyl fumarate) by Sandoz GmbH for multiple sclerosis relapsing-remitting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Dimherity (dimethyl fumarate)

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Sandoz GmbH. Decision date: 24/03/2022